Abstract
The EUROCARE studies represent an excellent example of a largely informal collaboration, which now involves over 80 cancer registries across 23 countries. Previous studies have studied differences in survival for individual cancers between countries for patients diagnosed in 1985–89 (EUROCARE-2) 1 Berrino F Capocaccia R Estève J et al. Survival of cancer patients in Europe: the EUROCARE-2 study. IARC Scientific Publications, number 151. IARC Press, Lyon1999 Google Scholar and 1990–94 (EUROCARE-3). 2 Berrino F Capocaccia R Coleman MP et al. Survival of cancer patients in Europe: the EUROCARE-3 study. Ann Oncol. 2003; 14: 1-155 PubMed Google Scholar Possible explanations for differences in survival have been explored for some cancers through so-called high-resolution studies. 3 Sant M Allemani C Capocaccia R et al. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer. 2003; 106: 416-422 Crossref PubMed Scopus (230) Google Scholar , 4 Gatta G Capocaccia R Sant M et al. Understanding variations in survival for colorectal cancer in Europe: a EUROCARE high resolution study. Gut. 2000; 47: 533-538 Crossref PubMed Scopus (222) Google Scholar , 5 Sant M Aareleid T Artioli ME et al. Ten-year survival and risk of relapse for testicular cancer: a EUROCARE high resolution study. Eur J Cancer. 2007; 43: 585-592 Summary Full Text Full Text PDF PubMed Scopus (49) Google Scholar These studies involved much smaller numbers of patients, but attempted to study the effect of disease stage at diagnosis and of treatment through analysis of individual patient records. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 studyIncreases in survival and decreases in geographic differences over time, which are mainly due to improvements in health-care services in countries with poor survival, might indicate better cancer care. Wealthy countries with high TNEH generally had good cancer outcomes, but those with conspicuously worse outcomes than those with similar TNEH might not be allocating health resources efficiently. Full-Text PDF Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 dataCancer-service infrastructure, prevention and screening programmes, access to diagnostic and treatment facilities, tumour-site-specific protocols, multidisciplinary management, application of evidence-based clinical guidelines, and recruitment to clinical trials probably account for most of the differences that we noted in outcomes. Full-Text PDF Does the UK really have an effective cancer plan?In this issue of The Lancet Oncology, we publish findings from EUROCARE-4: the largest international population-based analysis of cancer survival based on data from 83 registries in 23 countries. In keeping with earlier EUROCARE analyses (in 1995, 1999, and 2003), the latest findings show 5-year cancer survival in Europe continues to improve and rates in eastern Europe are catching up with western Europe. Cancer care is, therefore, getting better, and patients in Europe are achieving outcomes closer to those seen for patients treated in the USA. Full-Text PDF
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call